Nadofaragene Firadenovec Is Effective With Beneficial Dosing Schedule in Real-World for BCG-Unresponsive NMIBC
The favorable dosing schedule of nadofaragene firadenovec-vncg (Adstiladrin) makes it a suitable option for patients with BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC) who have to travel far for care, and patient selection must be done carefully as not to include those who are likely to leak the drug, according to Mark Tyson II, MD, MPH, and … Read more